PT - JOURNAL ARTICLE AU - Ashwin Aravindakshan AU - Jörn Boehnke AU - Ehsan Gholami AU - Ashutosh Nayak TI - The Impact of Mask-Wearing in Mitigating the Spread of COVID-19 During the Early Phases of the Pandemic AID - 10.1101/2020.09.11.20192971 DP - 2021 Jan 01 TA - medRxiv PG - 2020.09.11.20192971 4099 - http://medrxiv.org/content/early/2021/08/26/2020.09.11.20192971.short 4100 - http://medrxiv.org/content/early/2021/08/26/2020.09.11.20192971.full AB - Masks have been widely recommended as a precaution against COVID-19 transmission. Several studies have shown the efficacy of masks at reducing droplet dispersion in lab settings. However, during the early phases of the pandemic, the usage of masks varied widely across countries. Using individual response data from the Imperial College London — YouGov personal measures survey, this study investigates the effect of mask use within a country on the spread of COVID-19. The survey shows that mask-wearing exhibits substantial variations across countries and over time during the pandemic’s early phase. We use a reduced form econometric model to relate population-wide variation in mask-wearing to the growth rate of confirmed COVID-19 cases. The results indicate that mask-wearing plays an important role in mitigating the spread of COVID-19. Widespread mask-wearing within a country associates with an expected 7% (95% CI: 3.94% — 9.99%) decline in the growth rate of daily active cases of COVID-19 in the country. This daily decline equates to an expected 88.5% drop in daily active cases over a 30-day period when compared to zero percent mask-wearing, all else held equal. The decline in daily growth rate due to the combined effect of mask-wearing, reduced outdoor mobility, and non-pharmaceutical interventions averages 28.1% (95% CI: 24.2%-32%).Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A -- All data are publicly availableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll codes have been written in python 3.7 programming language. All data and codes are available at open sourced Github repository at https://github.com/ashutoshnayakIE/COVID-masks. Data is stored in pythons numpy format. However, the raw data can be procured from the sources mentioned in the references below (link for raw data set is also provided in the Github repository). https://github.com/ashutoshnayakIE/COVID-masks